Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We conducted a randomized trial of the treatment of multiple myeloma with high-dose chemotherapy followed by either one or two successive autologous stem-cell transplantations. METHODS: At the time of diagnosis, 399 previously untreated patients under the age of 60 years were randomly assigned to receive a single or double transplant. RESULTS: A complete or a very good partial response was achieved by 42 percent of patients in the single-transplant group and 50 percent of patients in the double-transplant group (P=0.10). The probability of surviving event-free for seven years after the diagnosis was 10 percent in the single-transplant group and 20 percent in the double-transplant group (P=0.03). The estimated overall seven-year survival rate was 21 percent in the single-transplant group and 42 percent in the double-transplant group (P=0.01). Among patients who did not have a very good partial response within three months after one transplantation, the probability of surviving seven years was 11 percent in the single-transplant group and 43 percent in the double-transplant group (P<0.001). Four factors were significantly related to survival: base-line serum levels of beta2-microglobulin (P<0.01) and lactate dehydrogenase (P<0.01), age (P<0.05), and treatment group (P<0.01). CONCLUSIONS: As compared with a single autologous stem-cell transplantation after high-dose chemotherapy, double transplantation improves overall survival among patients with myeloma, especially those who do not have a very good partial response after undergoing one transplantation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In earlier randomized trials, an improvement in OS was seen in two studies,132,133 but other studies failed to show such an improvement.134,135”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [132]
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Self-citationHigh-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Moreau, P. (2002) · Blood · doi:10.1182/blood.v99.3.731 · Cited by 564
Fermand, J.-P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., et al. (1998) · Blood · doi:10.1182/blood.v92.9.3131 · Cited by 542
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55 · Cited by 472
(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3832 · Cited by 433
INTENSIVE TREATMENT OF MULTIPLE MYELOMA AND CRITERIA FOR COMPLETE REMISSION
Gore, M. E., Viner, C., Meldrum, M., Bell, J., Milan, S., Zuiable, A., Slevin, M., Selby, P. J., Clark, P. I., Millar, B., et al. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91548-1 · Cited by 190
Research works printed but not linked: 7
- Barlogie B, 1991, Bone Marrow Transplant, 7, 71
- Fermand J-P, 1999, Blood, 94, 396a
- Blade J, 2001, Blood, 98, 815a
- Palumbo A, 2001, Blood, 98, 849a
- Fermand J-P, 2001, Blood, 98, 815a
- Richardson P, 2002, Blood, 100, 104a
- Sirohi B, 2002, Bone Marrow Transplant, 29, S12
Cited by
Items 201–300 of 987
Role of autologous and allogeneic stem cell transplantation in myeloma
Bensinger, W. (2009) · Leukemia · doi:10.1038/leu.2008.396 · Cited by 65
Rossi, J. M., Fegueux, N., Lu, Z., Legouffe, É., Exbrayat, C., Bozonnat, M., Navarro, R., Lopez, E., Quittet, P., Daurès, J., et al. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705138 · Cited by 61
Orsini, F., Rotschild, C., Beurrier, P., Faradji, A., Goudemand, J., & Polack, B. (2005) · PubMed · Cited by 65
Maiolino, Â., Hungria, V., Garnica, M., Oliveira-Duarte, G. B., de Oliveira, L. C. O., Mercante, D., MIRANDA, E. C. M., Quero, A. A., Peres, A. L., Barros, J. C., et al. (2012) · American Journal of Hematology · doi:10.1002/ajh.23274 · Cited by 64
Yasui, H., Hideshima, T., Hamasaki, M., Roccaro, A. M., Shiraishi, N., Kumar, S. K., Tassone, P., Ishitsuka, K., Raje, N. S., Tai, Y., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0838 · Cited by 63
Deleu, S., Lemaire, M., Arts, J., Menu, E., Valckenborgh, E. V., King, P., Broek, I. V., Raeve, H. D., Camp, B. V., Croucher, P. I., et al. (2009) · Leukemia · doi:10.1038/leu.2009.121 · Cited by 63
“Therefore, the identification of new key targets in both the MM cells and the BM microenvironment is crucial for the development of new therapeutic strategies”
BackgroundTumor antigen immunization of sibling stem cell transplant donors in multiple myeloma
Neelapu, S. S., Munshi, N. C., Jagannath, S., Watson, T. M., Pennington, R. M., Reynolds, C. G., Barlogie, B., & Kwak, L. W. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705057 · Cited by 57
Treatment for patients with newly diagnosed multiple myeloma in 2015
Mateos, M., Ocio, E. M., Paiva, B., Rosiñol, L., Martínez‐López, J., Bladé, J., Lahuerta, J. J., García‐Sánz, R., & Miguel, J. F. S. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.06.001 · Cited by 61
“Only two of the trials showed a benefit in terms of PFS [78,79] and one showed a better OS in favour of the tandem arm [78].”
BackgroundHiwase, D., Bollard, G. M., Hiwase, S. D., Bailey, M., Muirhead, J., & SCHWARER, A. P. (2007) · Cytotherapy · doi:10.1080/14653240701452800 · Cited by 58
Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs
Bensinger, W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6863 · Cited by 61
Tosi, P., Zamagni, E., Cellini, C., Parente, R., Cangini, D., Tacchetti, P., Perrone, G., Ceccolini, M., Boni, P., Tura, S., et al. (2006) · European Journal Of Haematology · doi:10.1111/j.0902-4441.2005.t01-1-ejh2520.x · Cited by 56
“improved these results (5, 6); however, the disease Tosi P, Zamagni E, Cellini C, Parente R, Cangini D, Tacchetti P, Perrone G, Ceccolini M, Boni P, Tura S, Baccarani M, Cavo M.”
ResultPark, J. H., Cho, Y. W., Son, Y. J., Kim, K., Chung, H., Jeong, S. Y., Choi, K., Park, C. R., Park, R., Kim, I.-S., et al. (2006) · Colloid & Polymer Science · doi:10.1007/s00396-005-1438-7 · Cited by 54
Fenk, R. R., Liese, V., Neubauer, F., Bruns, I., Kondakci, M., Balleisen, S., Saure, C., Schröder, T., Haas, R. R., & Kobbe, G. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.575967 · Cited by 56
“Likewise, patients not achieving at least a vgPR after a first HDT and autologous PBSCT have a better outcome when they receive a second, tandem HDT [6].”
BackgroundZver, S., Zadnik, V., Bunc, M., Rogel, P., Černelč, P., & Koželj, M. (2007) · International Journal of Hematology · doi:10.1532/ijh97.e0620 · Cited by 58
Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Chanan-Khan, A. A., Cohen, A. D., Devine, S. M., Djulbegović, B., Faber, E. A., Gasparetto, C., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0095 · Cited by 68
Raje, N. S., Vadhan‐Raj, S., Willenbacher, W., Terpos, E., Hungria, V., Spencer, A. G., Alexeeva, Y., Facon, T. T. F., Stewart, A. K., Feng, A. J., et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2015.96 · Cited by 53
Self-citationSimultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma
Baumann, P., Schneider, L., Mandl–Weber, S., Oduncu, F. S., & Schmidmaier, R. (2011) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32834c8683 · Cited by 52
Melphalan and its role in the management of patients with multiple myeloma
Falco, P., Bringhen, S., Avonto, I., Gay, F., Morabito, F., Boccadoro, M., & Palumbo, A. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.7.945 · Cited by 55
Severe autologous GVHD after hematopoietic progenitor cell transplantation for multiple myeloma
Drobyski, W. R., Hari, P., Keever-Taylor, C. A., KOMOROWSKI, R. A., & Grossman, W. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.295 · Cited by 52
Hamouda, M.-A., Belhacène, N., Puissant, A., Colosetti, P., Robert, G., Jacquel, A., Mari, B. P., Auberger, P., & Luciano, F. (2014) · Oncotarget · doi:10.18632/oncotarget.2193 · Cited by 54
“Multiple myeloma (MM) is a plasma cell malignancy [11] that remains incurable despite conventional treatment [12] or high-dose therapy [13].”
BackgroundPros and cons of frontline autologous transplant in multiple myeloma: the debate over timing
Kumar, S. K., Buadi, F. K., & Rajkumar, S. V. (2018) · Blood · doi:10.1182/blood-2018-08-825349 · Cited by 55
Boyle, E. M., Ashby, C., Tytarenko, R. G., Deshpande, S., Wang, H., Wang, Y., Rosenthal, A., Sawyer, J., Tian, E., Flynt, E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1507 · Cited by 49
Self-citationLovell, R., Dunn, J., Begum, G., Barth, N. J., Plant, T. D., Moss, P. A. H., Drayson, M. T., & Pratt, G. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05647.x · Cited by 50
Health related quality of life in patients with multiple myeloma undergoing a double transplantation
Groot, C. A. U., Buijt, I., Gloudemans, I. J. M., Ossenkoppele, G. J., van den Berg, H. P., & Huijgens, P. C. (2005) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2004.00346.x · Cited by 52
Engelhardt, M. M., Kleber, M., Udi, J., Wäsch, R., Spencer, A. G., Patriarca, F. F., Knop, S. T., Bruno, B., Gramatzki, M., Morabito, F., et al. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.487959 · Cited by 56
“A variety of strategies have been under evaluation to achieve higher CR rates in the first-line therapeutic setting; this includes the use of tandem-ASCT approaches, particularly for patients with insufficient response following an initial ASCT [72].”
BackgroundCR represents an early index of potential long survival in multiple myeloma
Wang, M., Delasalle, K. B., Feng, L., Thomas, S., Giralt, S., Qazilbash, M., Handy, B. C., Lee, J. J., & Alexanian, R. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.176 · Cited by 52
Ballen, K. K., Becker, P. S., Yeap, B. Y., Matthews, B. J., Henry, D. H., & Ford, P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.144 · Cited by 52
Liu, Y. M., Chen, X.-Q., Liang, H.-X., Zhang, F.-X., Zhang, B., Jin, J., Chen, Y., Cheng, Y.-X., & Zhou, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021930 · Cited by 49
“The use of high-dose chemotherapy followed by autologous stem cell transplantation as well as novel agents including thalidomide, bortezomib (BOR), and lenalidomide has increased remission rates and progression-free survival [4–7].”
BackgroundKharfan‐Dabaja, M. A., Hamadani, M., Reljic, T., Nishihori, T., Bensinger, W., Djulbegović, B., & Kumar, A. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-2 · Cited by 50
“In fact, outcomes from various studies comparing single auto-HCT versus tandem auto-auto approach have been discrepant [7,24,25] and a published meta-analysis failed to show OS benefit with tandem autografts [8].”
BackgroundResultWang, X., Sinn, A. L., Pollok, K. E., Sandusky, G. E., Zhang, S., Chen, L., Liang, J., Crean, C., Suvannasankha, A., Abonour, R., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08248.x · Cited by 50
“While highdose chemotherapy with stem cell support increases the proportion of complete responses, the effect on overall survival remains relatively modest, and all patients invariably relapse (Attal et al, 1996, 2003; Riccardi et al, 2000; Child et al, 2003).”
BackgroundBendamustine in patients with relapsed or refractory multiple myeloma
Michael, M., Bruns, I., Bölke, E., Zohren, F., Czibere, A. G., Safaian, N., Neumann, F., Haas, R. R., Kobbe, G., & Fenk, R. R. (2010) · European journal of medical research · doi:10.1186/2047-783x-15-1-13 · Cited by 47
Naumann‐Winter, F., Greb, A., Borchmann, P., Bohlius, J., Engert, A., & Schnell, R. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004626.pub3 · Cited by 55
How I treat the young patient with multiple myeloma
Gandolfi, S., Prada, C. P., & Richardson, P. G. G. (2018) · Blood · doi:10.1182/blood-2017-05-693606 · Cited by 56
Brinker, B. T., Waller, E. K., Leong, T. L., Heffner, L. T., Redei, I., Langston, A. A., & Lonial, S. (2006) · Cancer · doi:10.1002/cncr.21852 · Cited by 50
A Fas agonist induces high levels of apoptosis in haematological malignancies
Greaney, P., Nahimana, A., Lagopoulos, L., Etter, A.-L., Aubry, D., Attinger, A., Beltraminelli, N., Huni, B., Bassi, I., Sordat, B., et al. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.08.006 · Cited by 47
Role of Stem Cell Transplantation in Multiple Myeloma
Devarakonda, S. S., Efebera, Y. A., & Sharma, N. (2021) · Cancers · doi:10.3390/cancers13040863 · Cited by 48
“In the IFM94 study, which compared one with two successive autologous stem cell transplants following high dose chemotherapy, tandem transplantation resulted in improved EFS and OS [58].”
MethodZver, S., Zadnik, V., Černelč, P., & Koželj, M. (2008) · International Journal of Hematology · doi:10.1007/s12185-008-0112-5 · Cited by 52
“Very little is known about cardiac toxicity of the treatment regimen with CY as part of stem cell collection followed by two autologous HSCT treatments with myeloablative dosages of MEL given in a very short time [1, 3].”
BackgroundNew therapies in multiple myeloma
Merchionne, F., Perosa, F., & Dammacco, F. (2007) · Clinical and Experimental Medicine · doi:10.1007/s10238-007-0134-y · Cited by 50
Boiron, J.-M., Dazey, B., Cailliot, C., Launay, B., Attal, M., Mazurier, F., McNiece, I., Ivanović, Z., Caraux, J., Marit, G., et al. (2006) · Transfusion · doi:10.1111/j.1537-2995.2006.01001.x · Cited by 46
Self-citationProteasome inhibitor, bortezomib, for myeloma and lymphoma
Tobinai, K. (2007) · International Journal of Clinical Oncology · doi:10.1007/s10147-007-0695-5 · Cited by 50
Dumontet, C., Landi, S., Reiman, T., Perry, T., Pleșa, A., Bellini, I., Barale, R., Pilarski, L. M., Troncy, J., Tavtigian, S. V., et al. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.335 · Cited by 48
Abonour, R., Wagner, L. I., Durie, B. G. M., Jagannath, S., Narang, M., Terebelo, H. R., Gasparetto, C., TOOMEY, K. E., Hardin, J. W., Kitali, A., et al. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3446-y · Cited by 46
The impact of race on outcomes of autologous transplantation in patients with multiple myeloma
Verma, P. S., Howard, R. S., & Weiss, B. M. (2008) · American Journal of Hematology · doi:10.1002/ajh.21139 · Cited by 45
Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: Results of a Phase II Randomized Trial
Qazilbash, M. H., Saliba, R. M., Nieto, Y. L., Parikh, G. C., Pelosini, M., Khan, F. B., Jones, R. B., Hosing, C. M., Mendoza, F. L., Weber, D. M., et al. (2008) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.09.019 · Cited by 47
“These approaches include the combination of existing and novel antimyeloma agents in conventional doses [34], tandem ASCT [35,36], maintenance therapy [37], and sequential autologous and allogeneic transplantation [38].”
BackgroundBurington, B. E., Barlogie, B., Zhan, F., Crowley, J. J., & Shaughnessy, J. D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4568 · Cited by 46
Badros, A. Z., Goloubeva, O. G., Fenton, R. G., Rapoport, A. P., Akpek, G., Harris, C., Ruehle, K., Westphal, S., & Meisenberg, B. R. (2006) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2006.n.061 · Cited by 45
Symptom burden after autologous stem cell transplantation for multiple myeloma
Campagnaro, E. L., Saliba, R. M., Giralt, S., Roden, L., Mendoza, F. L., Aleman, A., Cleeland, C. S., Weber, D., Brown, J. O., & Anderson, K. O. (2008) · Cancer · doi:10.1002/cncr.23299 · Cited by 50
“1] Median Charlson score at transplantation 3 [2–6]”
BackgroundFenk, R. R., Michael, M., Zohren, F., Graef, T. T., Czibere, A. G., Bruns, I., Neumann, F., Fenk, B., Haas, R. R., & Kobbe, G. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701694194 · Cited by 46
“However, despite further intensification of high dose therapy [3,4] there is no cure for patients with multiple myeloma.”
BackgroundKopp, H., Yıldırım, S., Weisel, K. C., Kanz, L., & Vogel, W. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0499-7 · Cited by 47
“tandem high-dose approach (Attal et al. 2003).”
Multiple myeloma: New staging systems for diagnosis, prognosis and response evaluation
Rajkumar, S. V., & Buadi, F. K. (2007) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2007.10.002 · Cited by 47
Relationship Between Depth of Response and Outcome in Multiple Myeloma
Dingli, D., Pacheco, J. M., Nowakowski, G. S., Kumar, S. K., Dispenzieri, A. A., Hayman, S. R., Lacy, M. Q., Gastineau, D. A., & Gertz, M. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.7879 · Cited by 45
Prince, H. M., Simmons, P. J., Whitty, G. A., Wall, D. P., Barber, L., Toner, G. C., Seymour, J. F., Richardson, G. E., Mrongovius, R. I., & Haylock, D. N. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05081.x · Cited by 47
“This strategy appears beneficial in selected patients with myeloma (Attal et al, 2003) and relapsed or high-risk germ cell tumours (Bokemeyer et al, 1999).”
BackgroundMartino, M. V., Praticò, G., Messina, G., Irrera, G., Massara, E., Messina, G., Console, G., & Iacopino, P. (2006) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2006.00736.x · Cited by 47
Singhal, S., & Mehta, J. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03060906 · Cited by 56
“yr for patients who underwent tandem HSCT (30).”
BackgroundShimoni, A., Hardan, I., Ayuk, F. A., Schilling, G., Atanackovic, D., Zeller, W., Yerushalmi, R., Zander, A. R., Kröger, N. M., & Nagler, A. (2010) · Cancer · doi:10.1002/cncr.25228 · Cited by 42
“Matched unrelated donor 23 5 21 (4-58) 4 18 (2-33) F ! M .”
ResultSecond autologous transplant as salvage therapy in multiple myeloma
Atanackovic, D., & Schilling, G. (2013) · British Journal of Haematology · doi:10.1111/bjh.12579 · Cited by 45
“…transplant was demonstrated by randomized studies, but the benefit might be confined to those patients failing to achieve near-CR (nCR) or at least a very good partial response (VGPR) after the first transplant (Attal et al, 2003; Lahuerta et al, 2003; Cavo et al, 2007; Harousseau et al, 2009).”
BackgroundSanchorawala, V., Wright, D. G., Quillen, K., Finn, K. T., Dember, L. M., Berk, J. L., Doros, G. D., Fisher, C., Skinner, M. M., & Seldin, D. C. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705746 · Cited by 42
Georges, G. E., Maris, M. B., Maloney, D. G., Sandmaier, B. M., Sorror, M. L., Shizuru, J. A., Lange, T., Agura, E. D., Bruno, B., McSweeney, P. A., et al. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2006.11.011 · Cited by 45
Stem-cell transplantation in multiple myeloma
Harousseau, J., Moreau, P., Attal, M., Facon, T. T. F., & Avet‐Loiseau, H. (2005) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2005.01.005 · Cited by 42
Self-citationMultiple myeloma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Harousseau, J., & Dreyling, M. H. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp140 · Cited by 43
Self-citationMyelom, O. B. O. D. S. M., Knop, S. T., Engelhardt, M. M., Liebisch, P., Meisner, C., Holler, E., Metzner, B., Peest, D., Kaufmann, M., Bunjes, D. W., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0537-2 · Cited by 42
Schmidt‐Hieber, M., Blau, I. W., Trenschel, R., Andreesen, R., Stuhler, G., Einsele, H., Kanz, L., Keilholz, U., Marinets, O., Beelen, D. W., et al. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705605 · Cited by 41
Tinguely, M., Jenni, B., Knights, A. J., Lopes, B., Korol, D., Rousson, V., Fontecedro, A. C., Cogliatti, S., Bittermann, A. G., Schmid, U., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00738.x · Cited by 41
Clinical impact of chromosomal aberrations in multiple myeloma
Nahi, H., Sütlü, T., Jansson, M., Alici, E., & Gahrton, G. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02324.x · Cited by 43
The evolution of stem-cell transplantation in multiple myeloma
Mahajan, S., Tandon, N., & Kumar, S. K. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718761776 · Cited by 44
ESRD due to Multiple Myeloma in the United States, 2001–2010
Reule, S. A., Sexton, D. J., Solid, C. A., Chen, S., & Foley, R. N. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014090876 · Cited by 43
Jalili, A., Ozaki, S., Hara, T., Shibata, H., Hashimoto, T., Abe, M., Nishioka, Y., & Matsumoto, T. (2005) · Blood · doi:10.1182/blood-2005-04-1438 · Cited by 39
Stem Cell Transplantation for Multiple Myeloma: Current and Future Status
Giralt, S. (2011) · Hematology · doi:10.1182/asheducation-2011.1.191 · Cited by 41
A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
Hideshima, T., Raje, N., Richardson, P. G., & Anderson, K. C. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s1445 · Cited by 39
“Attempts to improve autografting include repeated use of high dose therapies (Desikan et al 2000; Attal et al 2003), as well as immune strategies to treat minimal residual disease post-transplant (Massaia et al 1999) can improve outcome in some studies, few, if any, patients are cured.”
Current therapeutic uses of lenalidomide in multiple myeloma
Hideshima, T., Richardson, P. G. G., & Anderson, K. C. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.2.171 · Cited by 37
“Attempts to improve autografting include repeated use of high-dose therapies [35,36], as well as immune strategies to treat minimal residual disease post transplant [37]; although outcome is improved in some studies, few (if any) patients are cured.”
BackgroundAntitumour and antiangiogenic effects of Aplidin® in the 5TMM syngeneic models of multiple myeloma
Caers, J., Menu, E., Raeve, H. D., LePage, D., Valckenborgh, E. V., Camp, B. V., Álvarez, E., & Vanderkerken, K. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604388 · Cited by 40
“…transplantation clearly provides an overall survival advantage, with an extended disease-free survival, while reduced-dose-intensity allogeneic transplantation has opened the door to many more patients for this treatment option (Kroger et al, 2002; Attal et al, 2003; Harousseau et al, 2005).”
BackgroundMRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment
Landgren, O., Lu, S. X., & Hultcrantz, M. L. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.03.001 · Cited by 40
Multiple myeloma: chemotherapy or transplantation in the era of new drugs
Palumbo, A., & Rajkumar, S. V. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01431.x · Cited by 39
Shah, G. L., Winn, A. N., Lin, P., Klein, A. K., Sprague, K., Smith, H. P., Buchsbaum, R. J., Cohen, J. T., Miller, K. B., Comenzo, R. L., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.05.013 · Cited by 40
“This is similar to the 3-year OS of younger patients of approximately 65% [5,31], although these studies were conducted before the use of novel agents.”
ResultBortezomib: Proteasome Inhibition as an Effective Anticancer Therapy
Richardson, P. G. G., & Mitsiades, C. S. (2005) · Future Oncology · doi:10.1517/14796694.1.2.161 · Cited by 40
Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma
Anderson, L. D., Cook, D. R., Yamamoto, T. N., Berger, C., Maloney, D. G., & Riddell, S. R. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1009-3 · Cited by 37
“Survival can be prolonged with autologous stem cell transplantation (SCT) and other therapy combinations [1–5], but the disease recurs in almost all patients.”
BackgroundMultiple myeloma maintenance therapy: A review of the pharmacologic treatment
Shank, B. R., Brown, V. T., & Schwartz, R. N. (2014) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155213514468 · Cited by 42
“2013–12:49pm] [1–16] //blrnas3/cenpro/ApplicationFiles/Journals/SAGE/3B2/OPPJ/Vol00000/130144/APPFile/SG-OPPJ130144.”
Giralt, S., Costa, L. J., Maloney, D. G., Krishnan, A. Y., Fei, M., Antin, J. H., Brunstein, C. G., Geller, N. L., Goodman, S. A., Hari, P., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.11.018 · Cited by 37
Laubach, J. P., Mitsiades, C. S., Roccaro, A. M., Ghobrial, I. M., Anderson, K. C., & Richardson, P. G. G. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190902866732 · Cited by 38
Palumbo, A., Falco, P., Ambrosini, M. T., Petrucci, M. T., Musto, P., Caravita, T., Pregno, P., Bertola, A., Cavallo, F., Ciccone, G., et al. (2005) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2005.00533.x · Cited by 38
Abdelkefi, A., Torjman, L., Romdhane, N. B., Ladeb, S., Omri, H. E., Othman, T. B., Elloumi, M., Bellaj, H., Lakhal, A., Jeddi, R., et al. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705050 · Cited by 37
RetractedLefrère, F., Mauge, L., Réa, D., Ribeil, J., Cortivo, L. D., Brignier, A., Aoun, C., Larghero, J., Cavazzana, M., & Miclea, J. M. (2012) · Transfusion · doi:10.1111/j.1537-2995.2012.03744.x · Cited by 35
Cowan, A. J., Baldomero, H., Atsuta, Y., Mikhael, J. R., Aljurf, M. D., Seber, A., Greinix, H., Koh, M., Worel, N., Libby, E. N., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.08.018 · Cited by 37
Critically ill cancer patients in the intensive care unit: short‐term outcome and 1‐year mortality
Mokart, D., Etienne, A., Esterni, B., Brun, J. P., Chow‐Chine, L., Sannini, A., Faucher, M., & Blache, J. (2011) · Acta Anaesthesiologica Scandinavica · doi:10.1111/j.1399-6576.2011.02579.x · Cited by 40
“5] Management in intensive care unit: Vasopressors 48 (43) Renal replacement therapy 30 (27) Noninvasive mechanical ventilation (MV) 46 (42) Noninvasive mechanical ventilation without conventional MV 23 (21) Conventional mechanical ventilation 54 (50) Infection: 85 (77) Microbiologically documented: 42 (49) Bacterial…”
BackgroundAdvances in therapy of multiple myeloma
Bladé, J., & Rosiñol, L. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3283136984 · Cited by 37
Targeted Therapy in Multiple Myeloma
Chng, W. J., Lau, L. G., Yusof, N., & Mow, B. M. F. (2005) · Cancer Control · doi:10.1177/107327480501200204 · Cited by 39
Cavo, M., Terragna, C., Renzulli, M., Zamagni, E., Tosi, P., Testoni, N., Nicci, C., Cangini, D., Tacchetti, P., Grafone, T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7506 · Cited by 35
The Changing Landscape of Myeloma Therapy
Cavo, M., & Baccarani, M. (2006) · New England Journal of Medicine · doi:10.1056/nejme058322 · Cited by 35
The evolution and impact of therapy in multiple myeloma
Laubach, J. P., Richardson, P. G. G., & Anderson, K. C. (2010) · Medical Oncology · doi:10.1007/s12032-010-9442-2 · Cited by 40
“survival. Historically, these have included tandem ASCT [ 37 , 38] and ASCT followed by maintenance therapy with either prednisone alone [39] or prednisone and interferon [40].”
MethodMark, T. M., Reid, W. L., Niesvizky, R., Gergis, U. S., Pearse, R. N., Mayer, S. A., Greenberg, J., Coleman, M., van Besien, K., & Shore, T. B. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.02.013 · Cited by 34
“The IFM 99-04 protocol showed a superior outcome in the tandem MEL200 group in those patients who failed to achieve a very good partial response or better after a single transplant [23].”
MethodTranslating the anti-myeloma activity of Natural Killer cells into clinical application
Fionda, C., Stabile, H., Molfetta, R., Soriani, A., Bernardini, G., Zingoni, A., Gismondi, A., Paolini, R., Cippitelli, M., & Santoni, A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.10.005 · Cited by 36
Baertsch, M., Mai, E. K., Hielscher, T., Bertsch, U., Salwender, H. J., Munder, M., Fuhrmann, S., Dührsen, U., Brossart, P., Neben, K., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-020-00390-3 · Cited by 36
Durie, B. G. M. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)70008-6 · Cited by 36
Durie, B. G. M. (2005) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2005.n.045 · Cited by 39
Cooling, L. L. W., Hoffmann, S., Herrst, M., Muck, C., Armelagos, H., & Davenport, R. D. (2009) · Transfusion · doi:10.1111/j.1537-2995.2009.02350.x · Cited by 37
“5 NS Immunoglobulin (mg/dL)¶ IgG (range) 596 (124-4940) 627 (139-4940) 449 (137-4440) NS IgA (range) 47 (6-1380) 67 (6-1380) 37 (6-478) 0.”
InfluentialState of the art therapy in multiple myeloma and future perspectives
Denz, U., Haas, P. S., Wäsch, R., Einsele, H., & Engelhardt, M. M. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.11.040 · Cited by 43
Faiman, B. M., Mangan, P. A., Spong, J., & Tariman, J. D. (2011) · Clinical journal of oncology nursing · doi:10.1188/11.cjon.s1.66-76 · Cited by 41
“Autologous stem cell transplantation has been well documented as an effective treatment for patients with newly diagnosed myeloma as well as for those with relapsed or refractory disease (Attal et al., 1996, 2002, 2003, 2006, 2010; McCarthy, Owzar, Anderson, Hofmeister, & Hurd, 2010).”
Kumar, S. K., Pérez, W. S., Zhang, M., Ballen, K. K., Bashey, A., To, L. B., Bredeson, C., Cairo, M. S., Elfenbein, G. J., Freytes, C. O., et al. (2008) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.07.011 · Cited by 36
“It will be difficult to extrapolate the results from tandem ASCT strategies to this population, given the lack of benefit in the randomized trials for the subgroup achieving a VGPR, a response state not assessable in the NSM group.(23) Data regarding measurement of serum free light chains, if available, would have pro…”
Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT
Kobbe, G., Bruns, I., Fenk, R. R., Czibere, A. G., & Haas, R. R. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.59 · Cited by 33
Fenk, R. R., Hieronimus, N., Steidl, U. U., Bruns, I., Graef, T. T., Zohren, F., Ruf, L., Haas, R. R., & Kobbe, G. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2006.06.002 · Cited by 33
Metadata
- Authors
- Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., Voillat, L., Sotto, J.-J., Grosbois, B., & Bataille, R.
- Affiliations
- Hôpital Purpan (FR)
- Hôpital Claude Huriez (FR)
- Centre Hospitalier Universitaire de Poitiers (FR)
- Centre Hospitalier Universitaire de Nice (FR)
- Centre Henri Becquerel (FR)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- CHU Dijon Bourgogne (FR)
- Centre Hospitalier Universitaire de Besançon (FR)
- Hôpital Albert Michallon (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-12-25
- Volume
- 349
- Issue
- 26
- Pages
- 2495-2502
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1982499121
- Cited by
- 984
- References
- 16
- Citations by year
- 2026: 3 · 2025: 13 · 2024: 18 · 2023: 14 · 2022: 22 · 2021: 20 · 2020: 33 · 2019: 18 · 2018: 35 · 2017: 28 · 2016: 24 · 2015: 37 · 2014: 38 · 2013: 53 · 2012: 42
- FWCI
- 34.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- multiple myeloma, autologous stem cell transplantation, high-dose chemotherapy, overall survival, event-free survival, very good partial response, beta2-microglobulin, lactate dehydrogenase, prognostic factors
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Dexamethasone, Doxorubicin, Female, Humans, Male, Middle Aged, Multiple Myeloma, Neoplasm Staging, Prognosis, Transplantation, Autologous, Vincristine, Survival Rate, Multivariate Analysis, Hematopoietic Stem Cell Transplantation, Disease-Free Survival, Transplantation Conditioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.